MedTrace Logo

Hypertension Monitoring in Glioma Patients Treated With Bevacizumab

NCT01046279 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2013-06-13

No results posted yet for this study

Summary

Prospective casecontrol study in glioma patients undergoing treatment with bevacizumab (Avastin). At present there are no data on the correlation between occurrence of arterial hypertension and clinical outcome in patients with glioma or anaplastic astrocytoma. We will investigate whether glioma patients developing hypertension under bevacizumab treatment have a better outcome in terms of progression free survival, response rate and overall survival than equally treated patients remaining normotensive. Moreover, we will describe the dynamics of change in blood pressure after administration of bevacizumab in those patients developing hypertension.

* Trial with medicinal product

Conditions

  • Glioma Patients

Interventions

DRUG

Bevacizumab

Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Lukas Zimmerli, MD · University Hospital Zurich, Internal Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046279 on ClinicalTrials.gov